Abstract:

Introduction and Target: Sitoreductive Surgery (SRC) and hypertermic intraperitoneal chemotherapy (HIPEC) are the recommended treatment approach for peritoneal mezotelyoma (PM). Here we offer our multidisciplinary treatment experience for PM. Method and Requirements: Thirty-eight patients were included in the study between January 2009 and December 2017. Patients' clinico-patological characteristics, treatment results, medical records and intraoperative peritoneal cancer index (PCI) scores were analyzed backward. A total of 38 patients (n = 22 women) with an average age of 61 (21-80) were assessed. SRC was administered to 23 patients (60.5 percent) and SRC + HIPEC was administered to 18 patients (47.3 percent). After postoperative early mortal cases (6 patients) were excluded, longer OS was obtained in patients treated with adjuvan therapy (p = 0. by 03). Patients with morbid pathology had a higher PCI value. Obesity, diabetes mellitus (DM) and CA125 levels were higher in patients with more than 1000 U / ml. ADJUVAN CHEMOTHERAPY has shown that SRC + HIPEC may heal the OS in PM patients. However, multi-treatment in PM patients with DM, high PCI value and pre-operative CA125 levels above 1000 IU / ml should be carefully evaluated.

Keywords: